Defend your choice between perioperative FLOT and preoperative CROSS chemoradiation for this specific Siewert II tumor.
Patient is presenting with an advanced disease with sever dysphagia, hence the need to commence definitive treatment immediately in addition to immediate relief of the dysphagia. ESOPEC ASCO 2024 demonstrated the superiority of perioperative FLOT, over preoperative CROSS, in terms of median overall survival and progression free survival. However, CHECKMATE 577 trial showed much better progression free survival and overall survival with preoperative CROSS + 1 year adjuvant Nivolumab compared to just preoperative CROSS alone. Extrapolation from the CHECKMATE 577 and ESOPEC ASCO 2024 trials show that perioperative FLOT is equivalent to preoperative CROSS + 1 year adjuvant Nivolumab appear to be equivalent ifor disease free survival and progression free survival; even though a non-inferiority trial is yet to be conducted.
The deduction for this is that perioperative FLOT which can be started immediately is equivalent to preoperative CROSS + 1 year adjuvant Nivolumab, which may require delay of 2- 3 weeks to commence, in an index patient requiring immediate commencement of treatment; hence perioperative FLOT is the most suitable regimen in this index patient.
Address the baseline neuropathy. Explain how you will adjust the oxaliplatin component of your systemic therapy plan.
Managing a patient with FLOT require that a baseline neuropathy assessment is done on the patient. This is because oxaliplatin which is an essential component of the FLOT regimen is associated with neuropathy which can be very debilitating.
We first assess for baseline cormorbid conditions that are associated with or may potentiate neuropathy in patients. These include hypertension, diabetes mellitus. Then perform a thorough neurological baseline assessment using the CTCAE from mild grade 1 to permanently debilitating Grade 4 neuropathy. If neuropathy is significant, consider removing oxaliplatin from the regimen.
If neuropathy develops or worsens during treatment, dose modification should be considered. As follows:
Grade 1- maintain dose but monitor closely
Grade 2- reduce Oxaliplatin to 65mg/m2 (from 85mg/m2) or delay cycle until recovery
Grade 3- Discontinue Oxaliplatin
Grade 4- Permanently discontinue
Establish a protocol for the structured monitoring of treatment-induced adverse events for this patient. Specify how you will track subjective toxicity markers between his clinic visits.
-
Baseline Evaluation & Pre-Treatment Profiling:
Safety screens (CBC, LFTs, renal function, cardiac ejection fraction, infectious screens).
Pharmacogenomic testing: Mandatory DPYD genotype/phenotype testing prior to 5-FU/Capecitabine administration.
Nutritional and functional assessments (ECOG performance status, MUST nutritional risk screening).
-
In-Clinic Structured Monitoring Framework (Formatted as Structured Sections):
Hematologic: ANC, Hemoglobin, Platelets (pre-cycle thresholds & G-CSF trigger criteria).
Gastrointestinal: Mucositis, Nausea/Vomiting, Diarrhea (dose reductions & C. difficile / ICI colitis workup).
Neurological: Oxaliplatin-induced acute dysesthesia vs. cumulative peripheral neuropathy (CTCAE dose modification rules).
Immune-Mediated Adverse Events (irAEs): Organ-specific screens (Pneumonitis, Colitis, Hepatitis, Endocrinopathies, Nephritis) with steroid escalation rules (0.5\text{--}2.0\text{ mg/kg/day}).
Metabolic & Renal: Electrolyte wasting (K⁺, Mg²⁺) and pre/post hydration protocols.
-
Between-Visit Subjective Marker Tracking (PRO Framework):
PRO-CTCAE Tool Integration: Daily temperature, bowel movement frequency, pain scores, and bi-weekly IADL functional interference logs.
Automated Alert Criteria: Thresholds for fever, severe diarrhea (watery stools/day above baseline), intractable emesis, and acute sensory changes.
Nurse Triage Protocols: Rapid phone/telehealth intervention pathways to handle early supportive care.
-
Emergency "Red Flag" Escalation:
Clinical features include Febrile Neutropenia, Upper GI Bleeding, Severe Dehydration, Acute Cardiorespiratory Distress).
Formulate a clinical strategy for the three-week waiting period. Argue whether it is safe to initiate systemic therapy before the full biomarker profile returns.
The deduction for this is that perioperative FLOT which can be started immediately is equivalent to preoperative CROSS + 1 year adjuvant Nivolumab, which may require delay of 2- 3 weeks to commence, in an index patient requiring immediate commencement of treatment; hence perioperative FLOT is the most suitable regimen in this index patient. When the biomarker test is out and is positive for HER 2 or PDL1 (>5%), then we can add appropriate targeted or immunotherapy to the established chemotherapy.